Rigel Pharmaceuticals, Inc.
(NASDAQ : RIGL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
3.26%201.961.2%$535.88m
GILDGilead Sciences, Inc.
4.69%76.190.9%$481.31m
BIIBBiogen Inc.
2.87%337.831.3%$395.69m
CELGCelgene Corporation
2.85%84.161.2%$348.84m
ILMNIllumina, Inc.
4.04%326.073.5%$309.67m
REGNRegeneron Pharmaceuticals, Inc.
5.35%397.742.6%$240.70m
ALXNAlexion Pharmaceuticals, Inc.
5.01%127.572.0%$225.84m
VRTXVertex Pharmaceuticals Incorporated
4.25%185.211.9%$219.44m
SRPTSarepta Therapeutics, Inc.
5.23%138.2116.4%$180.07m
AAgilent Technologies, Inc.
2.71%67.411.5%$161.75m
BMRNBioMarin Pharmaceutical Inc.
6.45%105.864.4%$144.10m
LGNDLigand Pharmaceuticals Incorporated
6.17%212.4223.3%$122.48m
VKTXViking Therapeutics, Inc.
6.75%15.160.9%$119.61m
NKTRNektar Therapeutics
2.40%50.265.6%$111.67m
EXASExact Sciences Corporation
2.86%67.6525.3%$105.96m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. It focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include Fostamatinib Oral SYK Inhibitor and R348 Topical Ophthalmic JAK/SYK Inhibitor. The company was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.